247 related articles for article (PubMed ID: 33753715)
1. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.
Birdwell C; Fiskus W; Kadia TM; DiNardo CD; Mill CP; Bhalla KN
Blood Cancer J; 2021 Mar; 11(3):64. PubMed ID: 33753715
[TBL] [Abstract][Full Text] [Related]
2. EVI1 induces autophagy to promote drug resistance via regulation of ATG7 expression in leukemia cells.
Niu Y; Yang X; Chen Y; Jin X; Li L; Guo Y; Li X; Xie Y; Zhang Y; Wang H
Carcinogenesis; 2020 Jul; 41(7):961-971. PubMed ID: 31593983
[TBL] [Abstract][Full Text] [Related]
3. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
4. The reciprocal link between EVI1 and miRNAs in human malignancies.
Lang WJ; Chen FY
Gene; 2018 Sep; 672():56-63. PubMed ID: 29879503
[TBL] [Abstract][Full Text] [Related]
5. Evi1 forms a bridge between the epigenetic machinery and signaling pathways.
Yoshimi A; Kurokawa M
Oncotarget; 2011 Jul; 2(7):575-86. PubMed ID: 21795762
[TBL] [Abstract][Full Text] [Related]
6. EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.
Paredes R; Schneider M; Stevens A; White DJ; Williamson AJK; Muter J; Pearson S; Kelly JR; Connors K; Wiseman DH; Chadwick JA; Löffler H; Teng HY; Lovell S; Unwin R; van de Vrugt HJ; Smith H; Kustikova O; Schambach A; Somervaille TCP; Pierce A; Whetton AD; Meyer S
Nucleic Acids Res; 2018 Sep; 46(15):7662-7674. PubMed ID: 29939287
[TBL] [Abstract][Full Text] [Related]
7. The role of EVI1 in myeloid malignancies.
Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
[TBL] [Abstract][Full Text] [Related]
8. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
[TBL] [Abstract][Full Text] [Related]
9. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
[TBL] [Abstract][Full Text] [Related]
10. Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.
Kataoka K; Kurokawa M
Cancer Sci; 2012 Aug; 103(8):1371-7. PubMed ID: 22494115
[TBL] [Abstract][Full Text] [Related]
11. The EVI1 gene in myeloid leukemia.
Nucifora G
Leukemia; 1997 Dec; 11(12):2022-31. PubMed ID: 9447815
[TBL] [Abstract][Full Text] [Related]
12. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
Su G; Lian X; Tan D; Tao H; Liu H; Chen S; Yin H; Wu D; Yin B
Leuk Lymphoma; 2015 Feb; 56(2):472-9. PubMed ID: 24828867
[TBL] [Abstract][Full Text] [Related]
14. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
[TBL] [Abstract][Full Text] [Related]
16. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
17. The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
Liu XX; Pan XA; Gao MG; Kong J; Jiang H; Chang YJ; Zhang XH; Wang Y; Liu KY; Chen Z; Zhao XS; Huang XJ
Int J Lab Hematol; 2023 Apr; 45(2):195-203. PubMed ID: 36358022
[TBL] [Abstract][Full Text] [Related]
18. Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.
Li F; He W; Geng R; Xie X
Clin Transl Oncol; 2020 Jan; 22(1):137-143. PubMed ID: 31054042
[TBL] [Abstract][Full Text] [Related]
19. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
20. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
Paredes R; Doleschall N; Connors K; Geary B; Meyer S
Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]